Hypertensive Crisis Following COVID‐19 Vaccination
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
The Journal of Clinical Pharmacology - 62(2022), 8, Seite 1047-1048 |
| Beteiligte Personen: |
Khani, Elnaz [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022, The American College of Clinical Pharmacology. |
|---|
| Umfang: |
2 |
|---|
| doi: |
10.1002/jcph.2037 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY008054347 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY008054347 | ||
| 003 | DE-627 | ||
| 005 | 20230307174150.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/jcph.2037 |2 doi | |
| 028 | 5 | 2 | |a JCPH_JCPH2037.xml |
| 035 | |a (DE-627)WLY008054347 | ||
| 035 | |a (WILEY)JCPH2037 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Khani, Elnaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypertensive Crisis Following COVID‐19 Vaccination |
| 264 | 1 | |c 2022 | |
| 300 | |a 2 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022, The American College of Clinical Pharmacology. | ||
| 700 | 1 | |a Entezari‐Maleki, Taher |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of Clinical Pharmacology |g 62(2022), 8, Seite 1047-1048 |w (DE-627)WLY008047286 |x 15524604 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2022 |g number:8 |g pages:1047-1048 |g extent:2 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 62 |j 2022 |e 8 |h 1047-1048 |g 2 | ||